Source comparison
CJC-1295 no DAC & Ipamorelin Daily Dose: Research Comparison
Baseline Protocol 100 mcg 400 mcg 2× daily (AM, PM) Initial response studies, dose-finding trials Entry-level dosing for assessing individual peptide sensitivity and tolerance Intermediate Protocol 200 mcg 800 mcg Standard GH secretagogue research, body compos
This comparison does not assign a generated winner or score.
- Baseline Protocol
- 100 mcg
- 400 mcg
- 2× daily (AM, PM)
- Initial response studies, dose-finding trials
- Entry-level dosing for assessing individual peptide sensitivity and tolerance
- Intermediate Protocol
- 200 mcg
- 800 mcg
- Standard GH secretagogue research, body composition studies
- Most widely used schedule in published research. Balances efficacy and injection burden
- Advanced Protocol
- 200–300 mcg
- 1,200–1,800 mcg
- 3× daily (AM, post-workout, PM)
- Maximum GH pulse studies, performance research
- Reserved for advanced studies examining upper limits of GH response
- Single Daily (Incorrect)
- 200–600 mcg
- 400–1,200 mcg
- 1× daily
- Not recommended for no-DAC peptides
- Fails to maintain pulsatile GH pattern due to short half-life. Ineffective for CJC-1295 no DAC
- The intermediate protocol (200 mcg twice daily) represents the consensus standard across peer-reviewed GH secretagogue research. Studies examining body composition changes, sleep quality, and metabolic markers typically use this schedule because it provides measurable GH elevation without requiring three-times-daily administration. Single-daily dosing appears in older studies that used CJC-1295 with DAC. Applying that schedule to the no-DAC version is a category error that negates the peptide's design intent.